Skip to main content

Advertisement

Fig. 3 | BMC Medical Ethics

Fig. 3

From: Umbrella and basket trials in oncology: ethical challenges

Fig. 3

The schema of the Lung-MAP study design with five initial sub-studies. Adult patients with recurrent or metastatic squamous cell carcinoma (SCC) after progression on first-line platinum-based chemotherapy could be eligible to register in the Lung-MAP trial. After signing an informed consent, their archival or fresh tumor biopsy sample was screened for genetic aberrations. Results of genomic testing were returned within 16 days. Then, all patients were originally assigned to one of five sub-studies and they were randomized to receive either standard of care or a specific agent tailored to their alteration. One of these sub-trials was called a “non-match” sub-study and it enrolled patients whose tumors did not harbor any of the genetic aberrations tested in other sub-studies [15, 16]

Back to article page